Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Achondroplasia: early-phase trial registry

4 of 10 indexed Achondroplasia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Achondroplasia: 10 US clinical trials tracked, 4 recruiting.

Achondroplasia is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is BioMarin Pharmaceutical, running 5 of these trials.

Enrollment posture brief

Registry condition achondroplasia

OPEN 4 | RECR 40% | LATE 1 | EARLY 5 | RANK #1724 | SPON 5

Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)

Acute Leukemia of Ambiguous 80%Acute Myeloid Leukemia Post 40%Achondroplasia (this)40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Achondroplasia

Achondroplasia lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Achondroplasia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Achondroplasia is recruiting below its size-band peers.

    4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Achondroplasia research.

    BioMarin Pharmaceutical accounts for 5 of 10 trials (50%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Achondroplasia trials plan to enrol fewer than 100 people.

    Median target enrolment is 92 among the 10 trials that report a genuine target (sentinel values excluded). 6 of those (60%) plan for fewer than 100 participants.

  4. Achondroplasia splits between interventional and observational designs.

    6 interventional and 4 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 25Phase 31

Open and recent trials

10 total, page 1 of 1

RECRUITING 170 participants

VIrtual STudy in Achondroplasia for the US (VISTA)

BioMarin Pharmaceutical

NCT06168201

RECRUITING Phase 2 92 participants

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

Tyra Biosciences

NCT06842355

RECRUITING Phase 2 77 participants

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

QED Therapeutics, a BridgeBio company

NCT07169279

RECRUITING Phase 2 72 participants

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

Ascendis Pharma A/S

NCT06079398

ACTIVE NOT RECRUITING 271 participants

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

QED Therapeutics, a BridgeBio company

NCT04035811

ACTIVE NOT RECRUITING Phase 3 119 participants

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

BioMarin Pharmaceutical

NCT03424018

ACTIVE NOT RECRUITING Phase 2 73 participants

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

BioMarin Pharmaceutical

NCT03989947

ACTIVE NOT RECRUITING Phase 2 30 participants

A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)

BioMarin Pharmaceutical

NCT02724228

COMPLETED 363 participants

A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia

BioMarin Pharmaceutical

NCT01603095

COMPLETED 91 participants

C-Type Natriuretic Peptide and Achondroplasia

Nemours Children's Clinic

NCT01541306

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 1

Named interventions

Most-linked intervention names on Achondroplasia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

BMN 111 Drug
2 trials
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. Drug
1 trials
Placebo for Navepegritide Drug
1 trials
Navepegritide Drug
1 trials
TYRA-300 0.50 mg/kg Drug
1 trials
TYRA-300 0.375 mg/kg Drug
1 trials
TYRA-300 0.25 mg/kg Drug
1 trials
TYRA-300 0.125 mg/kg Drug
1 trials

US sites by state

Facility locations filed on Achondroplasia trials. A trial with sites in several states counts in each.

Wisconsin 8 trials
California 8 trials
Texas 7 trials
Delaware 6 trials
Tennessee 5 trials
Ohio 5 trials
Maryland 5 trials
Illinois 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Achondroplasia page

10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Achondroplasia condition card totals 10 registered trials; most-linked intervention BMN 111; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.